CRP and COVID-19: Tocilizumab, an IL-6 receptor inhibitor, has been previously studied for its abilityto mitigate systemic inflammatory disease states25,26 and explored forCOVID-19–related inflammation, given the early link between IL-6 and mortality.7 COVID-19 cytokine storm is associated with high levels of inflammatorycytokines often IL-6, CRP, and ferritin.